David Redlick is a partner in the Corporate Practice Group. He joined the firm in 1975. Mr. Redlick is the co-chair of the Life Sciences Group, the former co-chair of Hale and Dorr's Corporate Department and a former member of the firm's Executive Committee.
Practice
Mr. Redlick's practice focuses on corporate and securities law, with an emphasis on public offerings, mergers and acquisitions, venture capital transactions and corporate collaborations. For over 30 years, Mr. Redlick has served as counsel for a broad range of clients, including public and private life sciences and high technology companies, investment banks, venture capital funds and real estate development and finance companies. In 2011, Mr. Redlick was rated by Chambers USA as a “star individual” and by Chambers Global as Band 1 in the Life Sciences: Corporate/Commercial category.
Recent Highlights
Representation of clients in:
Initial public offerings
- Emergent BioSolutions (issuer)
- Cynosure (issuer)
- Icagen (issuer)
- Eyetech Pharmaceuticals (issuer)
- Diatide (issuer)
- Idera Pharmaceuticals (issuer)
- Ascent Pediatrics (issuer)
- Thermo Vision (issuer)
- Renaissance Solutions (issuer)
- Breakaway Solutions (issuer)
- Aegerion (Leerink Swann and Lazard)
- NuPathe Inc. (Leerink Swann and Lazard)
- Altus Pharmaceuticals (Merrill Lynch and Morgan Stanley)
- Labopharm (Merrill Lynch and Bank of America)
- Targacept (Morgan Stanley)
- GTx (Goldman Sachs)
- Barrier Therapeutics (Morgan Stanley)
- Progenics Pharmaceuticals (Oppenheimer & Co.)
- Also represented PTC Therapeutics, TransMedics, Xanodyne and Voyager Pharmaceuticals and the underwriters for Aldagen, ActivBiotics and Archemix in withdrawn offerings
Follow-on equity offerings
- Savient Pharmaceuticals (issuer/common stock shelf takedowns)
- Idera Pharmaceuticals (issuer/common stock shelf takedown)
- LTX (issuer/common stock shelf takedown)
- Saucony (issuer/common stock)
- Altus Pharmaceuticals (Morgan Stanley)
- Alexion Pharmaceuticals (Goldman Sachs)
- Lexicon Genomics (Morgan Stanley)
- Vicuron Pharmaceuticals (Morgan Stanley)
- Barrier Therapeutics (Morgan Stanley)
- Progenics Pharmaceuticals (CIBC/UBS)
- GTx (Lazard)
- Fisher Scientific (Goldman Sachs)
Debt offerings
- Millennium Pharmaceuticals (issuer/144A convertible note offering and WKSI shelf convertible note offering)
- Thermo Electron (issuer/144A note offering)
- American Tower (issuer/144A note offering)
- Savient Pharmaceuticals (issuer/WKSI shelf convertible note offering)
- Transkaryotic Therapies (issuer/convertible note shelf takedown)
- AtheroGenics (issuer/144A convertible note offering)
- Cubist Pharmaceutics (Goldman Sachs/WKSI shelf convertible note offering)
Mergers and acquisitions – Life Sciences
- The acquisition of Millennium Pharmaceuticals by Takeda Pharmaceuticals
- The Medicines Company in its acquisitions of Targanta Therapeutics Corporation and Curacyte GmbH
- Millennium Pharmaceuticals in its acquisitions of COR Therapeutics, Leukosite, Chemgenics and IDM Pharma
- PAREXEL International Corporation in its acquisitions of California Clinical Trials and APEX International Clinical Research
- Transkaryotic Therapies in its acquisition by Shire Pharmaceuticals Group plc
- Eyetech Pharmaceuticals in its acquisition by OSI Pharmaceuticals
- Icagen in its acquisition by Pfizer
- Levitronix LLC in the sale of its medical products business to Thoratec Corp.
- Taligen Therapeutics in its acquisition by Alexion Pharmaceuticals
- Alnara Pharmaceuticals in its acquisition by Eli Lilly
- GlycoFi in its acquisition by Merck
- Domantis in its acquisition by GSK
- Xanthus Pharmaceuticals in its acquisition by Antisoma plc
- Xanodyne Pharmaceuticals in its product sale of Lysteda to Ferring
- Savient Pharmaceuticals in its dispositions of its BTG and Rosemont subsidiaries
- Millennium Pharmaceuticals in its acquisitions of the minority interests in Millennium Predictive Medicine and Millennium BioTherapeutics
Mergers and Acquisitions – Other
- Many acquisitions and dispositions of public companies, divisions of public companies and private companies for Thermo Fisher Scientific
- Many acquisitions and dispositions of public companies, divisions of public companies and private companies for PerkinElmer
- Many acquisitions and dispositions of divisions of public companies and private companies for Williams plc
- LTX in its merger of equals with Credence Systems
- Thermo Electron in its acquisitions of minority interests in seven publicly traded subsidiaries
- Berkshire Realty in its LBO by management, Blackstone and Goldman Sachs
- Berkshire Mortgage Finance in its acquisition by Deutsche Bank
- Saucony in its acquisition by Stride Rite
- American Property Finance in its acquisition by Wachovia from Emigrant Savings Bank
Private Equity
- Many investments representing investment funds and companies involving a range of debt, equity and convertible instruments. Fund clients include MPM Capital, Clarus Ventures, Frazier Healthcare, New Leaf Venture Partners, Flagship Ventures, Novartis BioVentures, Advanced Technology Ventures and Boston Millennia Partners
Corporate collaborations
- Merrimack Pharmaceuticals in its collaboration with Sanofi-Aventis
- Merrimack Pharmaceuticals in its collaboration with PharmaEngine
- The Medicines Company in its license of ApoA I Milano from Pfizer
- Wellstat Therapeutics in its license agreement with Sanofi-Aventis
- Concert Pharmaceuticals in its collaboration with GSK
- Ophthotech in its license agreement with PDL and Biogen
- Alpharma in its collaboration with IDEA
- The Medicines Company in the reacquisition of European rights to Angiox® from Nycomed
- Fabre-Kramer Pharmaceuticals in its collaboration with GSK
- Eyetech Pharmaceuticals in its collaboration with Pfizer
- Icagen in its collaborations with Pfizer, McNeil (J&J), Abbott and BMS
- Idera Pharmaceuticals in its collaborations with Novartis and Merck and its cross-license with Isis Pharmaceuticals
- Diatide in its collaboration with Nycomed
- Potentia in its collaboration with Alcon
- b3 bio in its collaboration with Roche
Professional Activities
Mr. Redlick has served as a:
- Member of the Overseers Committee of Brigham and Women’s Hospital
- Guest lecturer at Sloan School of Management of The Massachusetts Institute of Technology and Kellogg School of Management at Northwestern University on subject of biotechnology initial public offerings
- Member of the Executive Committee of the Board of Directors of the Greater Boston Chamber of Commerce
- Co-Chair of Governor William Weld’s Task Force on Marketing Massachusetts
- Member of the Board of Associates of the Whitehead Institute for Biomedical Research (affiliated with The Massachusetts Institute of Technology)
- Trustee of the Massachusetts College of Art
Honors and Awards
- Ranked as a star individual in the life sciences; corporate/commercial category by Chambers and Partners for the United States and in Band 1 globally
- Ranked in Band 1 in Massachusetts corporate/M&A category by Chambers USA: America's Leading Lawyers for Business
- Listed as a "Leading Lawyer" in the area of mergers, acquisitions and buyouts: venture capital and emerging companies in the 2009, 2010 and 2011 editions of The Legal 500 United States
- Recognized as one of the world's leading life sciences lawyers in Who's Who Legal: The International Who's Who of Life Sciences Lawyers
- Named to the 2005 BTI Client Service All-Star Team as a result of BTI Consulting Group's annual survey of corporate counsel at Fortune 1000 companies to identify those attorneys who provided the highest quality client service and achieved the greatest client satisfaction
- Selected by peers for inclusion in The Best Lawyers in America every year since 1995
- Ranked in the PLC Cross-border Life Sciences Handbook as a "leading lawyer"
- Named a "Massachusetts Super Lawyer" in corporate finance in Boston Magazine from 2004 – 2011
Publications
- Redlick, David E., Steven D. Singer, and Steven D. Barrett, "20 Questions for Your Lawyer About Biotech Alliances," The Journal of BioLaw & Business 7, no. 4 (2004).
- Redlick, David E., and Sarah Rothermel, "The Limited Partnership Alternative," MCLE Massachusetts Business Lawyering.
- Kapner, Virginia K., and David E. Redlick, "A Counselor's Dose of Preventive Medicine," Nature Biotechnology, Bioentrepreneur Supplement (June 2002).
Speaking Engagements
- Boston Biotech World Health Forum – Deal Structures – October 2011
- Ophthalmology Innovation Summit 2011 – Staged Buyouts-Getting to “Win-Win” – October 2011
- Leerink Swann Healthcare Leadership Forum – M&A Deal Making – September 2011
- MPM Capital Biotechnology Retreat 2011 – Strategic Perspectives on Innovation – May 2011
- Ophthalmology Innovation Summit 2010 – Do’s and Dont’s of Negotiating with Pharma Partners and Buyers – October 2010
- MPM Capital Biotechnology Retreat 2010 – Health Care M&A and Partnering Forum – May 2010
- MPM Capital Biotechnology Retreat 2009 – Partnering and Acquisitions – May 2009
- Biotechnology Industry Association General Counsels' Meeting – Auction Style Negotiations in M&A and Licensing Transactions – October 2008
- Mass Biotech Council Finance Committee – Running for the Exits – June 2008
- HBM Partners Retreat – U.S. Market Update – March 2008
- AIG Life Sciences – Current Litigation Trends in Biotechnology – September 2007
- National Association of Corporate Directors – Directors Speaking Out of School – September 2007
- Harvard Business School – Realizing the Potential of Your Innovations: The Role of the Principal Investigator–From Discovery to Commercialization – May 2007
- MPM Capital Biotechnology Retreat 2006 – A Dozen Questions for a Life Sciences Company From Inception to Exit – May 2006
- BIO 2006 Annual International Convention – Considerations in Structuring Biotech M&A Transactions – April 2006
- Mass Biotech Council Mass Opportunities Conference – IPOs and Life Afterwards – November 2005
- MPM Capital Biotechnology Retreat 2005 – Merger & Acquisition Trends – May 2005
- Mass Biotech Council Committee Day – Biotech 2005: A New World Order – Industry Dynamics and the Inevitability of M&A – January 2005
- 3rd Bavarian University Start-Up Conference – Financing University Spinouts in The United States – Munich, Germany – July 2004
- MPM Capital Biotechnology Retreat 2004 – Biotech Initial Public Offerings – May 2004
- Global Pharmaceutical Strategies 2004 – Biotech Company Perspectives on Key Deal Terms – New York, New York – May 2004
- MPM Capital Biotechnology Retreat 2003 – Biotech/Pharmaceutical Company Collaborations – June 2003
